Introduction {#s1}
============

Chronic infection with hepatitis B virus (HBV) is an important global health problem. Approximately 350 million people are chronically infected with hepatitis B virus worldwide, especially in developing countries, 25% of whom will die from long term sequelae, such as cirrhosis, liver failure and hepatocellular carcinoma, resulting in 600,000 to one million deaths annually [@pone.0100182-Custer1]. Patients who are suffering from significant hepatic inflammation and fibrosis are at high risk of those complications [@pone.0100182-Yu1]. Assessment of liver significant fibrosis is critical to establishing effective clinical practice. It could be of great help for a doctor to determine patients\' suitability and the optimal time for antiviral therapy to achieve the best curative effects as well as to prevent excessive medication [@pone.0100182-Gumusay1]. In addition, early prediction of cirrhosis is beneficial to reducing complications in patients with chronic viral hepatitis [@pone.0100182-Liaw1].

Liver biopsy, an invasive technique, is the gold standard for the assessment of fibrosis. It has several disadvantages, such as patients\' reluctance, pain, hemoperitoneum, and pneumothorax, etc. [@pone.0100182-Bravo1]. In addition, its accuracy in assessing fibrosis is questionable because of sampling errors and intra- and inter-observer variations [@pone.0100182-Colloredo1]. Therefore, many people are beginning to realize the importance of prediction of liver fibrosis by noninvasive biomarkers.

Aspartate aminotransferase-to-platelet ratio index (APRI), the fibrosis index based on the 4 factors (FIB-4) and FibroTest are examples of noninvise biomarkers predicting liver fibrosis based on routinely available clinical parameters [@pone.0100182-Kim1]. They were initially used in Western populations with hepatitis C virus (HCV) or HCV/ human immunodeficiency virus (HIV) co-infection [@pone.0100182-Sterling1] and had good performance. The area under the receiver operating characteristic (AUROC) curve of FibroTest for detecting significant fibrosis peaked out at 0.85 [@pone.0100182-Poynard1], and the AUROC curve of APRI and FIB-4 reached 0.80 [@pone.0100182-Corradi1] and 0.81 [@pone.0100182-Amorim1] respectively. For detecting cirrhosis, FibroTest also has the best result, and its AUROC curve topped out at 0.90 [@pone.0100182-Shaheen1]. The AUROC curve of APRI and FIB-4 are 0.83 [@pone.0100182-Lin1] and 0.89 [@pone.0100182-Martinez1], respectively. These three markers can be considered as "good", even "better" markers, according to the criteria of Deeks JJ [@pone.0100182-Deeks1]. Consequently, the researchers were regularly conducting those markers to predict significant fibrosis and cirrhosis among HBV-infected patients. APRI was first used to predict significant fibrosis or cirrhosis in patients with HBeAg-negative chronic hepatitis B by Chrysanthos et al. [@pone.0100182-Chrysanthos1]. They found APRI was strongly correlated to the fibrosis. Later FIB-4 and FibroTest were successively used to predict HBV-related fibrosis.

However, due to the fact that those markers were initially derived from evaluation of HCV-related fibrosis, their accuracy for HBV patients was under constant debate among the researchers. Some scholars indicated that all of those noninvasive markers were able to predict significant fibrosis or cirrhosis among HBV patients, and could potentially be used to decrease the number of liver biopsies [@pone.0100182-Kim1]. Others maintained that those markers were not directly applicable to evaluation of HBV-related fibrosis because of the small AUROC curve [@pone.0100182-Wang1]. Therefore, we decided to conduct this meta-analysis to assess the pooled performance of these biomarkers for prediction of significant fibrosis and cirrhosis among HBV-infected patients. It could provide the basis for future research and clinical application.

Methods {#s2}
=======

Literature Search {#s2a}
-----------------

The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [@pone.0100182-Moher1] (see Checklist S1 for PRISMA checklist). A protocol (see [Text S1](#pone.0100182.s010){ref-type="supplementary-material"}) was developed and systematic methods were used to identify relevant studies, assess study eligibility for inclusion, and evaluate study quality. Online database search was completed on PubMed, EMBASE and the Cochrane Library (01/2003-04/2013) for terms including the following: aspartate aminotransferase-to-platelet ratio index, APRI, fibrosis index based on the 4 factors, FIB-4, FibroTest, hepatitis B virus, HBV, Chronic hepatitis B, CHB, fibrosis and cirrhosis (see [Text S2](#pone.0100182.s011){ref-type="supplementary-material"} for full search strategies). Additional studies were identified via a manual search for the referenced studies and review articles. EndNote X5 software was used to manage the references.

Selection Criteria {#s2b}
------------------

Studies were included if they met the following inclusion criteria: (a) The study evaluated the performance of the APRI and/or FIB-4 and/or FibroTest for the prediction of fibrosis and/or cirrhosis in HBV infected patients. Studies on patients with other etiologies of liver disease were also included if data for HBV-infected patients could be independently extracted. In addition, special populations of HBV patients (*e.g*., HBV/HIV coinfection, HBV/HCV, and HBV/ hepatitis D virus \[HDV\]) were also included. (b) Liver biopsy was used to diagnose liver fibrosis as a golden standard. (c) Data could be extracted to construct at least one 2×2 table of test performance, based on some cutoff points of the APRI, FIB-4, and FibroTest for a fibrosis stage. (d) They assessed the diagnostic accuracy for fibrosis stage F≥2 or F≥4 according to METAVIR or a comparable staging system. (e) The study included at least 40 patients. Studies of smaller sample sizes were excluded due to concerns on their applicability.

Data Extraction and Quality Assessment {#s2c}
--------------------------------------

Two reviewers (XYX and RXS) screened the downloaded titles and abstracts against the inclusion criteria. Two reviewers (XYX and HK) independently evaluated study eligibility, graded the study quality, and extracted data from the study. Any disagreements between the reviewers were resolved with detailed discussions between them together with a third reviewer (HBL). The parameters in our literature search included author, year of publication, region, method, patient gender, age, number of patients, underlying chronic liver disease etiology, histological scoring system, average length of liver specimen, time interval between biopsy and laboratory tests, prevalence of the fibrosis stage, as well as cutoff values to identify the fibrosis stage [@pone.0100182-Lin1].

The quality of included studies was independently appraised by two reviewers (XYX and YHZ) using the quality assessment of diagnostic accuracy studies (QUADAS) questionnaire [@pone.0100182-Whiting1] (see [Text S3](#pone.0100182.s012){ref-type="supplementary-material"}). It could estimate the internal and external validity of diagnostic accuracy studies used in systematic reviews.

Statistical Analysis and Data Synthesis {#s2d}
---------------------------------------

We extracted and tabulated the data in a series of 2×2 tables, which included sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) at each threshold value. The primary outcome was the identification of significant fibrosis, defined by METAVIR [@pone.0100182-Group1], Batts and Ludwig [@pone.0100182-Batts1], and Scheuer [@pone.0100182-Scheuer1] for stages F2 through F4, and Ishak [@pone.0100182-Ishak1] for stages F3 through F6. This gauge was chosen because significant fibrosis is often considered a threshold for the initiation of antiviral therapy [@pone.0100182-Strader1]. We also assessed cirrhosis (METAVIR, Batts and Ludwig, and Scheuer F4, and Ishak F5-6). In order to provide clinically meaningful results, the metrics of diagnostic test accuracy were examined.

The SROC curve, generated using linear regression, represents the relationship between the true positive rate and false positive rate across these studies, albeit they may have used different test thresholds [@pone.0100182-Walter1]. In this analysis, the area under SROC curve was examined according to Moses et al. [@pone.0100182-Moses1], and each study was weighted with its sample size and with adjustment for the number of thresholds within each study [@pone.0100182-Dukic1].

The diagnostic odds ratio (DOR) describes the odds of a positive test in true disease cases compared with cases of no disease [@pone.0100182-Deeks1]. The summary DOR was calculated using a DerSimonian and Laird random-effects model on a logarithmic scale with a corresponding test of heterogeneity [@pone.0100182-DerSimonian1]. Because such analyses require a single measure of accuracy for each study and many studies reported multiple test thresholds, we calculate the average DOR among all thresholds for a given study [@pone.0100182-Doust1]. We also calculated summary sensitivities and specificities using the bivariate meta-analytic approach [@pone.0100182-Reitsma1]. Pairs of sensitivity and specificity for diagnostic thresholds are jointly analyzed, with any correlation that might exist between those two measures taken into account using a random-effects approach.

The heterogeneity (or the lack of homogeneity) of the results between studies was assessed statistically using the Cochran-Q and the quantity I2. I2 value describes the percentage of total variation across studies that is attributable to heterogeneity rather than chance [@pone.0100182-Higgins1]. A meta-regression was conducted to further explore the covariates that may induce heterogeneity, according to the following predefined characteristics: (a) study design (retrospective or prospective); (b) etiology (HBV, HBV\[HBeAg negative\], or co-infection with other virus); (c) length of liver specimen (≥10 mm, ≥15 mm, ≥20 mm, or not); (d) liver biopsy scoring system (METAVIR, Ishak, Scheuer, Batts and Ludwig, and the Chinese Hospital System); (e) QUADAS score; (f) sample size; (g) median age (≤30, 31--40,41--50, or \>50); (h) percentage of males; (i) location of study (Europe or Asia); (j) prevalence of significant fibrosis/cirrhosis.

The potential publication bias was assessed using the Deeks funnel plots (the logarithm of the DOR plotted against ) [@pone.0100182-Deeks2]. is proportional to the square root of (1/n1+1/n2), where n1 is the number diseased and n2 not diseased. Data analyses were performed using the Meta-Disc software (v. 1.4).

Results {#s3}
=======

Search Results {#s3a}
--------------

The study selection process is presented with a flow chart in [Figure 1](#pone-0100182-g001){ref-type="fig"}. 306 studies were retrieved with the described search strategies, of which 196 were excluded following title and abstract screening. The full texts of 110 potentially eligible reports were obtained for further assessment. Of those, 30 papers were included in the review following full-text screening ([Table 1](#pone-0100182-t001){ref-type="table"}); 20 studies were related to the APRI [@pone.0100182-Gumusay1], [@pone.0100182-Chrysanthos1], [@pone.0100182-Wang1], [@pone.0100182-Zhou1]-[@pone.0100182-Sebastiani2], 13 studies related to the FIB-4 [@pone.0100182-Gumusay1], [@pone.0100182-Kim1], [@pone.0100182-Wang1], [@pone.0100182-Seto1]--[@pone.0100182-Liu2], [@pone.0100182-Bonnard1], [@pone.0100182-Zhang1], and 11 studies related to the FibroTest [@pone.0100182-Sebastiani1]--[@pone.0100182-Sebastiani2], [@pone.0100182-Myers1]--[@pone.0100182-Kim4].

![Flow diagram of article selection.](pone.0100182.g001){#pone-0100182-g001}
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###### Characteristics of the 31 Studies Included in the Meta-analysis.

![](pone.0100182.t001){#pone-0100182-t001-1}

  Test                         Author, Year, Regin         Study/Center Description     N    Interval Between Biopsy&Predictive index   Mean Age (%male)    Etiology     Liver biopsy System   length of liver specimen   Prevalence F2-4/F4   QUADAS Score
  ---------------------- ------------------------------- ---------------------------- ----- ------------------------------------------ ------------------ ------------- --------------------- -------------------------- -------------------- --------------
  APRI                          Zhou, 2010, China          Retrospective, 4 centers    146                  Same time                       35(84%)            HBV             Scheuer                 \>15 mm                 58%,10%              13
  APRI                          Lin, 2008, TaiWan         Retrospective, one center    48                    Unclear                        56(83%)            HBV             METAVIR                 Unclear                  NA,38%              12
  APRI                          Shin, 2008, Korea         Retrospective, one center    264                   Unclear                        28(87%)            HBV             METAVIR                  22 mm                   53%,3%              13
  APRI                          Kim, 2007, Korea           Retrospective, 2 centers    346                  Same time                       34(90%)            HBV          Batts Ludwing              Unclear                 75%,23%              13
  APRI                      Chrysanthos, 2005, Greece     Retrospective, one center    205                  Same time                       51(75%)         HBV(eAg-)           Ishak                   ≥15 mm                 60%,27%              12
  APRI                          Liu, 2007, China           Retrospective, 2 centers    444                   \<1 week                       30(71%)            HBV             Scheuer                 \>10 mm                  29%,6%              14
  APRI                      Guzelbulut, 2011, Turkey      Retrospective, one center    250                   Unclear                        39(58%)            HBV              Ishak                  Unclear                 26%,16%              11
  APRI                      Lesmana, 2011, Indonesia      Retrospective, one center    117                   Unclear                        41(54%)            HBV             METAVIR                  ≥15 mm                  62%,3%              13
  FIB-4                         Kim, 2009, Korea          Retrospective, one center    668                   \<2 days                       39(66%)            HBV          Batts Ludwing               ≥15 mm                 79%,34%              12
  FIB-4                        Zhang, 2010, China         Retrospective, one center    212                   Unclear                        31(88%)            HBV             Scheuer                  20 mm                  76%,21%              11
  FibroTest                    Myers, 2003, France        Retrospective, one center    209                  \<6 months                      39(70%)          HBV+HDV           METAVIR                 Unclear                  29%,9%              14
  FibroTest                  Miailhes, 2011, France         Prospective, 2 centers     59                    Unclear                        43(84%)          HBV+HIV           METAVIR                58%≥15 mm                61%,20%              14
  FibroTest                   Bottero, 2009, France          Cohort, multicenter       108                  \<6 months                      42(90%)        HBV+HIV/HDV         METAVIR               17.0±7.3 mm               56%,15%              10
  FibroTest                     Kim, 2012, Korea          Retrospective, one center    194                  Same time                       47(61%)            HBV          Batts Ludwing               ≥20 mm                 85%,39%              14
  FibroTest               Stibbe, 2011, The Netherlands   Retrospective, one center    48                   \<6 months                      37(73%)            HBV             METAVIR                  ≥20 mm                 46%,10%              12
  FibroTest                     Park, 2013, Korea          Retrospective, 3 centers    330                  Same time                       44(61%)            HBV          Batts Ludwing               ≥20 mm                 80%,24%              13
  FibroTest                     Gui, 2008, China          Retrospective, one center    100                  Same time                       35(78%)            HBV              Ishak                   ≥15 mm                 39%,12%              14
  FibroTest                     Kim, 2012, Korea          Retrospective, one center    170                  Same time                       45(60%)            HBV          Batts Ludwing               ≥20 mm                 71%,28%              12
  APRI/FIB-4                    Seto, 2011, China          Prospective, one center     237                  Same time                       32(67%)            HBV              Ishak                 15--20 mm                 32%,2%              13
  APRI/FIB-4                    Liu, 2012, China           Retrospective, 2 centers    114                  Same time                       38(80%)            HBV         China hospital             15--20 mm                51%,11%              14
  APRI/FIB-4                    Zhu, 2011, China          Retrospective, one center    175                   \<7 days                       37(78%)            HBV             METAVIR                 \>15 mm                 45%,17%              14
  APRI/FIB-4                     Wu, 2010, China          Retrospective, one center    78                    Unclear                        33(85%)            HBV             METAVIR               18.2±3.4 mm               41%,12%              13
  APRI/FIB-4                    Wang, 2012, China         Retrospective, one center    231                  Same time                       34(68%)            HBV             Scheuer                  ≥15 mm                  29%,7%              14
  APRI/FIB-4                   Ucar, 2013, Turkey         Retrospective, one center    73                   Same time                       45(64%)            HBV             METAVIR                 Unclear                 56%,11%              14
  APRI/FIB-4                  Gumusay, 2011, Turkek        Prospective, one center     58                    Unclear                        41(57%)            HBV              Ishak                   ≥20 mm                  17%,NA              13
  APRI/FIB-4                   Basar, 2013, Turkey        Retrospective, one center    76                   Same time                       45(45%)            HBV             METAVIR                  ≥10 mm                 67%,17%              14
  APRI/FIB-4                    Wang, 2012, China         Retrospective, multicenter   349                  Same time                       37(92%)         HBV(eAg-)          Scheuer                  ≥10 mm                  60%,7%              13
  APRI/FIB-4                    Liu, 2011, china          Retrospective, one center    623                   \<1 week                       32(55%)            HBV             METAVIR                  ≥10 mm                  35%,6%              14
  APRI/FT                    Sebastiani, 2011, Italy      Retrospective, multicenter   253                  Same time                       44(73%)          HBV+HDV           METAVIR                 Unclear                  58%,8%              13
  APRI/FT                    Sebastiani, 2007, Italy      Retrospective, one center    110                  Same time                       43(73%)            HBV             METAVIR                  ≥15 mm                 68%,20%              12
  APRI/FIB-4/FibroTest        Bonnard, 2010, France        Prospective, one center     59                   Same time                       35(69%)            HBV             METAVIR                 21±6 mm                 70%,24%              14

APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis index based on the 4 factors; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; QUADAS, The quality assessment of diagnostic accuracy studies.

Characteristics of the Included Studies {#s3b}
---------------------------------------

In the twenty APRI studies, a total of 4,208 patients (median age 36 yr, 72% male) were included. The overall prevalence of significant fibrosis and cirrhosis were 47% (ranged 17%--70%) and 11% (7%--27%), respectively. The liver biopsy scoring system used to classify the histology varied. 10 studies used a METAVIR score, 4 studies used an Ishak score, 4 studies used a Scheuer score, 1 study used a Batts and Ludwig score, and 1 study used the Chinese Hospital System. Nineteen of these studies (N = 3,955) included HBV-infected patients without comorbid conditions [@pone.0100182-Gumusay1], [@pone.0100182-Chrysanthos1], [@pone.0100182-Wang1], [@pone.0100182-Zhou1]--[@pone.0100182-Bonnard1]. The one remaining study included special populations of patients such as HBV/HDV-coinfected patients (N = 253) [@pone.0100182-Sebastiani3]. According to the QUADAS scale, eight studies met all 14 requirements of this scale, nine studies met 13, two studies met 12, and one study met 11.

A total of 2,953 patients (median age 36 yr, 70% male) were included in the thirteen studies on FIB-4. The overall prevalence of significant fibrosis and cirrhosis were 53% (ranged 17%--76%) and 15% (11%--34%), respectively. All those studies (N = 2,953) included HBV-infected patients without comorbid conditions. The liver biopsy scoring system used to classify the histology varied. Six studies used a METAVIR score, three studies used a Scheuer score, two studies used an Ishak score, one study used a Batts and Ludwig score, and one study used the Chinese Hospital System. Seven studies met all 14 requirements of the QUADAS scale, 4 studies met 13, 1 study met 12, and one study met 11.

There were 1,640 patients (median age 42 yr, 69% male) used to assess the performance of FibroTest in eleven studies. The overall prevalence of significant fibrosis and cirrhosis were 63% (ranged 39%--85%) and 20% (8%--39%), respectively. Seven of these studies (N = 1,011) included HBV-infected patients without comorbid conditions [@pone.0100182-Sebastiani1], [@pone.0100182-Bonnard1], [@pone.0100182-Kim3]--[@pone.0100182-Kim4]. The four remaining studies included special populations with HBV/HDV-coinfected patients (N = 462) [@pone.0100182-Sebastiani2], [@pone.0100182-Myers1], HBV/HIV-coinfected patients (N = 59) [@pone.0100182-Miailhes1], and HBV/HDV/HIV-coinfected patients (N = 108) [@pone.0100182-Bottero1]. According to the Quality Assessment of Diagnostic Accuracy Studies scale, we can see that 5 studies met all 14 requirements of this scale, 2 study met 13, 3 studies met 12, and 1 study met 10.

Diagnostic Accuracy for the Prediction of Significant Fibrosis {#s3c}
--------------------------------------------------------------

In the seventeen studies assessing the APRI (N = 3,573), the AUROC curve ranged from 0.61 to 0.86. When combined, the area under the SROC curve was 0.77 08 (SE = 0.0172) ([Figure 2A](#pone-0100182-g002){ref-type="fig"}). The Pooled DOR was 5.41 (95% confidence interval \[CI\] 3.98--7.35) ([Figure 2B](#pone-0100182-g002){ref-type="fig"}). The Cochran-Q *and I^2^* value of all measures were 38.32 and 58.2%, indicating significant heterogeneity across the included studies (*P* = 0.001) ([Figure 2B](#pone-0100182-g002){ref-type="fig"}). The pooled sensitivities and specificities could not be assessed. Instead, the sensitivities and specificities of the APRI at various diagnostic thresholds in the seventeen studies are listed in [Table 2](#pone-0100182-t002){ref-type="table"}. We used the meta-regression analysis to explore the heterogeneity of the APRI accuracy for detecting significant fibrosis, which was mainly affected by median age (*P* = 0.0211, see [Text S4](#pone.0100182.s013){ref-type="supplementary-material"} for meta-regression). There was no significant correlation between other covariates and the DOR.

![Meta-analysis of Hepatitis B-Related significant fibrosis.\
(A) SROC curve of the APRI; (B) Diagnostic odds ratio of the APRI.](pone.0100182.g002){#pone-0100182-g002}
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###### Diagnostic Accuracy of APRI for the Prediction of Significant Fibrosis in Various Studies.
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  Author,Year          Cutoff   Sensitivity   Specificity   PPV   NPV     AUROC(95%CI)
  ------------------- -------- ------------- ------------- ----- ----- ------------------
  Sebastiani, 2011      1.5         36%           98%       96%   53%   0.64(0.58--0.70)
  Seto, 2011            0.5         89%           41%       42%   89%   0.71(0.63--0.80)
                        1.5         29%           88%       55%   72%  
  Bonnard, 2010          1          56%           50%       72%   33%   0.61(0.46--0.76)
  Zhou, 2010            0.5         82%           38%       54%   71%         0.72
                        1.5         48%           86%       75%   66%  
  Shin, 2008            0.5         97%           34%       63%   91%   0.86(0.82--0.91)
                         1          87%           66%       75%   82%  
                        1.4         78%           83%       84%   77%  
                        1.5         75%           83%       83%   74%  
                         2          58%           89%       86%   65%  
  Wu, 2010              0.5         84%           35%       47%   76%   0.71(0.59--0.83)
                        1.5         46%           80%       63%   68%  
  Wang, 2012            0.5         58%           79%       54%   82%   0.77(0.71--0.84)
  Ucar, 2013            0.54        73%           59%       70%   63%         0.66
  Chrysanthos, 2005     0.5         79%           35%       65%   53%          NA
                        1.5         33%           83%       75%   45%  
  Liu, 2007             0.4         72%           75%       54%   87%         0.77
  Guzelbulut, 2011      0.5         87%           45%       36%   91%   0.78(0.72--0.84)
                        1.5         38%           91%       60%   81%  
  Lesmana, 2011         0.24        64%           70%       78%   54%   0.69(0.60--0.79)
  Gumusay, 2011         0.7         70%           87%       54%   93%         0.82
  Basar, 2013           0.43        62%           68%       80%   47%   0.67(0.55--0.79)
  Wang, 2012            0.5         53%           86%       86%   56%         0.78
                        1.5         22%           98%       95%   46%  
  Liu, 2011             0.3         69%           71%       56%   82%   0.76(0.73--0.8)
  Sebastiani, 2007      0.5         70%           85%       91%   58%   0.72(0.58--0.86)
                        1.5         26%           94%       91%   38%  

APRI, aspartate aminotransferase-to-platelet ratio index; AUROC, area under the receiver operating characteristic; PPV, positive predictive value; NPV, negative predictive value; 95%CI, 95% confidence interval.

In the ten studies assessing the FIB-4 for the prediction of significant Fibrosis (N = 1,996), the AUROC curve ranged from 0.69 to 0.77. When combined, the area under the SROC curve was 0.75 (SE = 0.0168) ([Figure 3A](#pone-0100182-g003){ref-type="fig"}). The summary DOR was 5.3 (95% CI 4.3--6.6), and the score of Cochran-Q is 7.54 (*P* = 0.581) ([Figure 3B](#pone-0100182-g003){ref-type="fig"}). The result from the analysis of the heterogeneity was statistically insignificant. The summary sensitivities and specificities of the FIB-4 were 65.8% (95% CI 62.4%--69.1%) and 73.6% (95% CI 70.8%--76.3%), respectively ([Figure S1](#pone.0100182.s001){ref-type="supplementary-material"}--[S2](#pone.0100182.s002){ref-type="supplementary-material"}).

![Meta-analysis of Hepatitis B-Related significant fibrosis.\
(A) SROC curve of the FIB-4; (B) Diagnostic odds ratio of the FIB-4.](pone.0100182.g003){#pone-0100182-g003}

The AUROC curve ranged from 0.69 to 0.90 in the 11 studies assessing the FibroTest (N = 1.640). When combined, the area under the SROC curve was 0.84 (SE = 0.0227) ([Figure 4A](#pone-0100182-g004){ref-type="fig"}). The summary DOR was 13.73 (95% CI 8.61--21.90), and the score of Cochran-Q is 22.52, indicating significant heterogeneity across the included studies (*P* = 0.0127) ([Figure 4B](#pone-0100182-g004){ref-type="fig"}). We didn\'t find the cause of the heterogeneity of FibroTest accuracy according to the predefined characteristics. But center description might affect heterogeneity beyond the predefined design (See [Text S5](#pone.0100182.s014){ref-type="supplementary-material"}).

![Meta-analysis of Hepatitis B-Related significant fibrosis.\
(A) SROC curve of the FibroTest; (B) Diagnostic odds ratio of the FibroTest.](pone.0100182.g004){#pone-0100182-g004}

Diagnostic Accuracy for the Prediction of Cirrhosis {#s3d}
---------------------------------------------------

There were 11 studies on assessing the APRI for the predication of cirrhosis (N = 2,083). The AUROC curve of these studies ranged from 0.50 to 0.83. When combined, the area under the SROC curve was 0.75 (SE = 0.0174) ([Figure 5A](#pone-0100182-g005){ref-type="fig"}). The summary DOR was 4.4 (95% CI 2.9--6.8). The heterogeneity occurred in the meta-analysis for the twelve studies assessing the APRI for the predication of cirrhosis, which was statistically significant (Q = 23.10, *P* = 0.01; *I^2^* = 56.7%, [Figure 5B](#pone-0100182-g005){ref-type="fig"}). However, when we further conducted the meta-analysis at the different thresholds of \<1.0, 1.0, and 2.0, we found that the heterogeneity wasn\'t statistically significant ([Figure S3](#pone.0100182.s003){ref-type="supplementary-material"}). The summary sensitivity and specificity of the APRI at different diagnostic thresholds are listed in [Table 3](#pone-0100182-t003){ref-type="table"}.

![Meta-analysis of Hepatitis B-Related cirrhosis.\
(A) SROC curve of the APRI; (B) Diagnostic odds ratio of the APRI.](pone.0100182.g005){#pone-0100182-g005}
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###### Summary Sensitivities and Specificities of the APRI at Different Diagnostic Thresholds for the Prediction of Cirrhosis.
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  Test Threshold    Number of Studies   SROC   Summary Sensitivity(95%CI)   Summary Specificity(95%CI)
  ---------------- ------------------- ------ ---------------------------- ----------------------------
  \<1.0                 5(1,228)        0.76         84% (79%--88%)               54% (51%--58%)
  1                     6(1,471)        0.76         62% (55%--68%)               75% (72%--77%)
  2                     6(1,409)        0.79         29% (23%--35%)               89% (87%--91%)

APRI, aspartate aminotransferase-to-platelet ratio index; 95%CI, 95% confidence interval.

According to the meta-regression analysis, the heterogeneity of APRI accuracy for detecting cirrhosis was mainly affected by etiology (*P* = 0.0159) (See [Text S6](#pone.0100182.s015){ref-type="supplementary-material"}), whereas the other covariates were not significant. After excluding the only one study which included HBV/HDV-coinfected patients, the pooled DOR was 5.03 (95% CI 3.45--7.35) and heterogeneity was no longer significant (Q = 14.05, *P* = 0.1204; *I^2^* = 36.0%).([Figure S4](#pone.0100182.s004){ref-type="supplementary-material"}) According to the meta-analysis, the pooled sensitivity and specificity were 60.9% (95% CI 55.0--66.6%) and 74.8% (72.4--77.1%), respectively ([Figures S5](#pone.0100182.s005){ref-type="supplementary-material"}--[S6](#pone.0100182.s006){ref-type="supplementary-material"}).

The AUROC curve in the six studies assessing the FIB-4 (N = 1,304) ranged from 0.74 to 0.93. When combined, the area under the SROC curve was 0.87 (SE = 0.0307) ([Figure 6A](#pone-0100182-g006){ref-type="fig"}). The summary DOR was 12.97 (95% CI 6.91--24.35) and the score of Cochran-Q is 10.01 (*P* = 0.07) ([Figure 6B](#pone-0100182-g006){ref-type="fig"}). The analysis showed that the heterogeneity was statistically insignificant. The summary sensitivities and specificities of the FIB-4 were 44.7% (95% CI 39.4%--50.2%) and 86.6% (95% CI 84.3%--88.7%), respectively ([Figures S7](#pone.0100182.s007){ref-type="supplementary-material"}--[S8](#pone.0100182.s008){ref-type="supplementary-material"}).
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In the nine studies assessing the FibroTest (N = 1101), the AUROC curve ranged from 0.68 to 0.92. When combined, the area under the SROC curve was 0.90 (SE = 0.0250) ([Figure 7A](#pone-0100182-g007){ref-type="fig"}). The summary DOR was 23.75 (95% CI 11.88--47.48) and the score of Cochran-Q is 20.25 (*P* = 0.0094) ([Figure 7B](#pone-0100182-g007){ref-type="fig"}). The heterogeneity was statistically significant. The pooled sensitivities and specificities could not be assessed. Instead, the sensitivities and specificities of the FibroTest at various diagnostic thresholds in the nine studies are listed in [Table 4](#pone-0100182-t004){ref-type="table"}.

![Meta-analysis of Hepatitis B-Related cirrhosis.\
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10.1371/journal.pone.0100182.t004

###### Diagnostic Accuracy of FibroTest for the Prediction of Significant Fibrosis and Cirrhosis in Various Studies.

![](pone.0100182.t004){#pone-0100182-t004-4}

  Author,Year         Cutoff   Sensitivity   Specificity   PPV    NPV      AUROC(95%CI)
  ------------------ -------- ------------- ------------- ------ ------ ------------------
  Sebastiani, 2011     0.48        54%           83%       81%    57%    0.69(0.63--0.75)
  Myers, 2003          0.2         89%           52%       43%    92%    0.78(0.74--0.82)
                       0.4         54%           80%       52%    81%   
                       0.6         34%           93%       68%    78%   
                       0.8         18%           99%       92%    75%   
                        1          8%           100%       100%   73%   
  Miailhes, 2011       0.38        77%           85%       89%    72%    0.86(0.75--0.96)
  Bottero, 2009        0.48        70%           72%       77%    65%    0.77(0.68--0.86)
  Bonnard, 2010        0.37        78%           78%       89%    61%    0.79(0.66--0.91)
  Kim, 2012            0.32        79%           93%       98%    45%    0.90(0.84--0.97)
  Stibbe, 2011         0.31        86%           69%       70%    86%           NA
  Park, 2013           0.32        75%           77%       93%    43%           NA
  Gui, 2008            0.31        79%           79%       70%    86%    0.84(0.75--0.93)
                       0.4         74%           92%       85%    85%    0.84(0.75--0.93)
                       0.72        28%           98%       92%    68%    0.84(0.75--0.93)
  Kim, 2012            0.31        75%           96%       98%    61%    0.9(0.85--0.94)
  Sebastiani, 2007      F2         80%           91%       95%    68%    0.85(0.75--0.95)
  Cirrhosis                                                             
  Sebastiani, 2011     0.75        42%           91%       51%    88%    0.68(0.63--0.73)
  Miailhes, 2011       0.58       100%           81%       56%    100%   0.92(0.85--0.99)
  Bottero, 2009        0.73        75%           85%       46%    95%    0.87(0.79--0.94)
  Bonnard, 2010        0.5         86%           82%       60%    95%    0.85(0.74--0.96)
  Kim, 2012            0.68        80%           92%       87%    87%    0.87(0.82--0.92)
  Stibbe, 2011         0.75       100%           7%        11%    100%          NA
  Gui, 2008            0.55        83%           84%       42%    97%    0.86(0.71--1.00)
  Kim, 2012            0.67        91%           85%       85%    91%    0.88(0.83--0.94)
  Sebastiani, 2007      F4         55%           97%       80%    89%    0.76(0.67--0.85)

According to the meta-regression analysis, the heterogeneity of FibroTest accuracy for detecting cirrhosis was mainly affected by sample size (*P* = 0.0385) and median age (*P* = 0.0436) ([Text S7](#pone.0100182.s016){ref-type="supplementary-material"}), whereas the other covariates were not significant.

Publication Bias {#s3e}
----------------

Funnel plots of these three markers for assessing possible publication bias are illustrated in [Figure 8](#pone-0100182-g008){ref-type="fig"}. Mild asymmetry was noted in the funnel plots of the FIB-4 and FibroTest.

![Funnel plot of publication bias.\
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Discussion {#s4}
==========

Liver fibrosis progression is commonly found in HBV-infected patients. Cirrhosis develops in approximately one third of those cases, usually after an extensive period of time during which liver biochemical indices are found to be predominantly or even persistently abnormal [@pone.0100182-Custer1]. Patients with significant fibrosis or cirrhosis should be considered for antiviral therapy, which can potentially reverse cirrhosis and reduce complications [@pone.0100182-Lavanchy1]. Considering the limitations and risks of biopsy, the researchers make persistent efforts in exploring some noninvasive markers in order to more accurately identify patients with significant fibrosis or cirrhosis. APRI, FIB-4 and FibroTest are such noninvasive markers gaining increasing acceptance in clinical practice. Those markers may reduce the need for liver biopsy and may help to monitor the efficacy of treatment [@pone.0100182-Sebastiani1].

In our systematic review, the diagnostic accuracy of the APRI, FIB-4 and FibroTest for HBV-related significant fibrosis and cirrhosis has been comprehensively evaluated and summarized on a large scale, and we confirmed the results of many individual studies. Our meta-analysis also included the description of multiple measures of test performance using confirmed meta-analytic techniques and formal assessment for publication bias and heterogeneity, as well as exploratory analysis. All results should be valid and reasonably reliable.

FibroTest had the best result in not only significant fibrosis but also cirrhosis. The area under the SROC curve of FibroTest is bigger and even reaches the standard of "better" on cirrhosis [@pone.0100182-Deeks1], and the summary sensitivity and specificity have reached 84% and 82%, respectively. A meta-analysis about HCV-infected patients showed that the area under the SROC curve of significant fibrosis and cirrhosis are 0.81 and 0.90 [@pone.0100182-Shaheen1]. Evidently, the performance of FibroTest in evaluating HBV-related fibrosis is no worse than HCV-related. Therefore, FibroTest could be considered as a better marker in assessing fibrosis and cirrhosis of HBV-infected patients. The FibroTest, however, is calculated with alpha2 macroglobulin, alpha2 globulin (or haptoglobin), gamma globulin, apolipoprotein A1, GGT and total bilirubin [@pone.0100182-ImbertBismut1]. Alpha2 macroglobulin and alpha2 globulin (or haptoglobin) are not routine clinical measurements, and those two indicators are not tested for patients in most hospitals. Furthermore they cost more than conventional indicators. Those factors may bring restrictions to the wider application of the FibroTest in clinical practice.

The calculation method of FIB-4 is simpler than that of FibroTest. The area under the SROC curve of FIB-4 predicting HBV-related significant fibrosis and cirrhosis are 0.75 and 0.87, respectively. FIB-4 also has a better performance of predicting fibrosis [@pone.0100182-Kim1]. Its test items are easy to obtain in clinical practice, although its predictive results are not as good as FibroTest [@pone.0100182-Amorim1], [@pone.0100182-Martinez1]. APRI shows lower diagnostic accuracy than FibroTest and Fib-4 to identify HBV-related significant fibrosis and cirrhosis. It has been introduced to assess HBV-related fibrosis the earliest because of its simple and easy practice. Presently, APRI is widely utilized in identifying the degree of fibrosis and cirrhosis of patients with hepatitis C and hepatitis B, particularly in regions with limited healthcare resources. Some scholars argue that the calculation method of APRI did not consider the factor of spleen size [@pone.0100182-Kim2]. If patients were grouped by spleen size, the performance of APRI in predicting HBV-related fibrosis would be improved. Our meta-analysis revealed that the area under the SROC curve of APRI was small and the accuracy of the evaluation of HBV-related fibrosis was poor. Our results showed similar performance of APRI for staging of significant fibrosis and cirrhosis [@pone.0100182-Jin1].

Meta-regression method was convenient and reliable to screen the factors of heterogeneity. The strength of our study is that meta-regression analysis has been used to explore several factors that may be responsible for heterogeneity. Liver biopsy scoring systems and percentage of males emerged from many relevant factors to provide heterogeneity to summary test result on APRI to predict significant fibrosis [@pone.0100182-Jin1]. On the other hand, etiology of cirrhosis was found to be significantly associated with the heterogeneity on APRI to predict cirrhosis. But the heterogeneity of the meta-analysis of the FIB-4 and FibroTest to predict significant fibrosis and cirrhosis was not statistically significant. FIB-4 and FibroTest to predict fibrosis had better consistency, and summary test results were reasonably reliable.

However, there are several limitations in our systematic review. Firstly, we only focused our analysis on those patients with HBV-related fibrosis, without distinguishing between HBeAg negative and positive cases, or considering the virus replication rate due to the limited number of publications. Secondly, we included studies published in English and Chinese languages only, so the language bias may influence the results to some extent. Lastly, Fibroscan, a widely noninvasive tool, was not considered in this meta-analysis, because our focus was to compare the serum markers calculated by biochemical examination.

In summary, the FibroTest has excellent diagnostic accuracy for the identification of HBV-related significant fibrosis and cirrhosis. But FibroTest is seldom applied in clinical practice as a result of expensive cost. FIB-4, a relatively moderate marker, has better summary diagnostic accuracy and could be measured and calculated relatively easily. Furthermore, APRI shows some limited value in identifying hepatitis B-related significant fibrosis and cirrhosis. All of them have their own advantages and disadvantages. Future studies of novel fibrosis markers are needed to demonstrate improved accuracy and cost-effectiveness compared with those simple, economical, and widely available indeces.
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